Key Highlights
- Octave® Bioscience receives a $10M grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) for pioneering Parkinson’s disease biomarker research.
- Development of a custom protein biomarker panel aimed at measuring Parkinson’s disease activity and progression, addressing critical unmet needs in the Parkinson’s community.
- Leveraging MJFF’s robust data resources, including The MJFF Parkinson’s Progression Markers Initiative (PPMI), for groundbreaking research in Parkinson’s disease diagnostics.
Source: Business Wire
Notable Quotes
- “This project is incredibly meaningful to us, as it further extends our mission to build precision care solutions that transform the lives of people living with high cost, complex, and debilitating neurodegenerative conditions,” – William Hagstrom, Founder and CEO at Octave Bioscience
- “The Parkinson’s community has an unmet need for deeper, objective, and more precise insights that are based on the individual patient’s biology,” – Mark Frasier, PhD, Chief Scientific Officer at The Michael J. Fox Foundation
- “Our goal is to create a powerful biomarker tool that addresses a variety of applications ranging from disease activity and progression, disease staging and subtyping, as well as disease modifying treatment development and monitoring,” – Jim Eubanks, PhD, National Director of Medical Affairs at Octave Bioscience
SoH's Take
Octave Bioscience’s latest achievement in securing a significant grant from MJFF marks a pivotal step in the journey towards more effective management of Parkinson’s disease. The focus on developing a custom protein biomarker panel is not just a scientific advancement; it represents a beacon of hope for those affected by Parkinson’s. This initiative underscores the critical role of innovative biomarker research in understanding and combating neurodegenerative diseases. By leveraging MJFF’s extensive resources and Octave’s expertise in biomarker technology, this collaboration could very well pave the way for groundbreaking developments in Parkinson’s disease diagnostics and treatment, enhancing the quality of life for patients worldwideLike
